Therapie der obstruktiven Schlafapnoe mittels Alaxo stent

Translated title of the contribution: Treatment of obstructive sleep apnea with the Alaxo stent

A. Freuschle, C. Heiser, J. T. Maurer, K. Hörmann, B. A. Stuck

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Introduction: Continuous positive airway pressure (CPAP) is currently the gold standard in the treatment of obstructive sleep apnea (OSA). Despite its beneficial effects, however, acceptance and compliance is limited. Among the various alternative treatment options, a nasopharyngeal stent (AlaxoStent) has been introduced to stabilize the upper airway. Controlled trials, however, are currently lacking. Material and methods: We intended to test the clinical effects of a nasopharyngeal stent with a prospective controlled clinical trial. After a 2-week treatment period, one night of polysomnography with and one night without having the stent in place were scheduled. Inclusion criteria were as follows: age between 18 and 75 years, documented obstructive sleep apnea (5/h ≤ Apnea-Hypopnea Index ≤∈40/h), velopharyngeal obstruction, and CPAP intolerance. The main exclusion criteria were a BMI >∈35 kg/m 2 and relevant nasal obstruction. Results: Between January 2011 and August 2012 participation in the trial was offered to patients meeting the above mentioned criteria. Within this time period only 22 patients were willing to test the stent. None of those patients, however, were able to use and tolerate the stent during the planned treatment period of 14 days. Discussion: The AlaxoStent

Translated title of the contributionTreatment of obstructive sleep apnea with the Alaxo stent
Original languageGerman
Pages (from-to)212-214
Number of pages3
Issue number3
StatePublished - Sep 2013


Dive into the research topics of 'Treatment of obstructive sleep apnea with the Alaxo stent'. Together they form a unique fingerprint.

Cite this